Generics 2

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Decitabine manufacturers

2 products found

Filters

Filters

Filters , active

Country of origin : Argentina

Clear all

2 products found

decitabine

Vials, injection 50 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
WHO
Manufacturer #15160
This pharmaceutical company specializes in the production of oncological medications, including both oral solids and injectables. Their state-of-the-art manufacturing facility adheres to strict GMP standards for quality control and produces a range of products covering various oncology therapy areas. They operate globally with a presence in over 15 countries across regions like North America and the EU. The company prioritizes research and development, constantly seeking new formulations and improving existing ones. They hold multiple certifications and are committed to ensuring the safety, efficacy, and accessibility of their oncological medications.

Manufacturer usually replies in 5 days

Want to see all 2 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

What is the Decitabine drug?

Decitabine is a chemical analog of cytidine, a nucleoside present in DNA and RNA. Decitabine drug is used for the treatment of myelodysplastic syndromes, and for acute myeloid leukemia. As a cancer medicine, Decitabine slows the growth and spread of cancer cells. In the US, the FDA approved the medical use of Decitabine in 2006.

Decitabine manufacturers and wholesalers:

Decitabine's most known brand name is Dacogen by Otsuka Pharmaceuticals Co, Ltd. Some of Decitabine suppliers are Accord Healthcare, Cipla, and Chemi Spa. Decitabine suppliers market it in the form of lyophilized powder for solution for injection of 50 mg/20 ml or 50 mg/10ml.

Decitabine for sales:

In the US, Dacogen powder for injection 50 mg can cost from $324.50 to $1706.4.
On Pipelinepharma pharmaceutical market place, Linagliptin is most available from Turkey, India, Argentina, and China. The online platform helps the distributors to find qualified Linagliptin manufacturers globally, ensuring you they are not fraudulent websites. Using the integrated search engine of the marketplace, you can find a list of many pharmaceutical products for sale, including Linagliptin. Each Linagliptin manufacturer or supplier product description encompasses lots of information about the medication such as form, dose, manufacturing site approvals, and regulatory status. Then using the simple one-click contact form, you can enquire about the supply price if none are listed and place an order or send inquiries to companies no matter where they are in the world. Not only is this marketplace good news for distributors and other buyers, but wholesale sellers and manufacturers benefit as well. They can register and list an unlimited number of pharmaceutical products free of charge.

How to use Decitabine drugs?

There are two ways to be administered Decitabine for treatment. The first one is 15 mg/m2 IV over 3 hours; the patient should repeat every 8 hours for three days and repeat this cycle every six weeks. The second one is 20 mg/m2 IV over 1 hour; the patient should repeat this daily for five days and repeat this cycle every four weeks. Taking Decitabine can cause some side effects, the most common ones include black, tarry stools, bladder pain, bleeding after defecation, bleeding gums, blood in the urine or stools, blue lips and fingernails.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation